Loading
A phase 3 trial of Neladalkib, Alectinib in non-small-cell lung cancer and small-cell lung cancer, run by Nuvalent Inc., now recruiting.
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC is a phase 3 interventional study registered as NCT06765109 by Nuvalent Inc., with 450 participants planned, started 2025-07-17 and due to reach its primary completion in 2029-12. Interventions recorded: Neladalkib (NVL-655), Alectinib. Conditions listed: Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Neladalkib, Nuvalent, ALK-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares NVL, Nuvalent, Small-molecule kinase inhibitors.
Shares Alectinib, ALK-positive non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Alectinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Nuvalent, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Alectinib, Small-cell lung cancer, Non-small-cell lung cancer.
Shares ALK-positive non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Alectinib, ALK-positive non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/